A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma

Trial Profile

A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs AMG 232 (Primary) ; Dabrafenib; Trametinib
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 12 Jul 2017 Planned End Date changed from 1 Jun 2021 to 17 Aug 2021.
    • 12 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 15 Apr 2018.
    • 06 Jun 2017 Results (n=21) assessing the toxicity, maximum tolerated dose, pharmacokinetics, and preliminary antitumor activity of AMG 232 plus trametinib and dabrafenib in patients with TP53 wild type metastatic cutaneous melanoma, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top